ImmunoGen, Inc. has selected Cytovance Biologics for process development, cell banking and cGMP manufacturing of a proprietary ImmunoGen antibody.
   
Cytovance will use its 44,000-sq.-ft., multi-product cGMP production facility in Oklahoma City, OK for the project. Cytovance specializes in the production of clinical antibody and recombinant protein products derived from cell culture at scales as high as 500L (w/v) from both fed-batch and perfusion processes.
   
“We are very pleased to partner with ImmunoGen and provide manufacturing excellence to their products,” said Darren Head president and chief executive officer of Cytovance. “Our relationship with ImmunoGen is an excellent example of our business model, value, services and state-of-the-art facilities.”